TEST:

Breast Cancer Index®

Furthermore, the hydrogel demonstrated excellent strain sensing performance, with a gauge factor (GF) of 2.7 in the 0-75 % strain range and fast self-recovery, making it a promising material for dynamic wearable sensing devices. This work highlights the successful integration of material optimization and structural design, offering a new approach for development of next-generation flexible bioelectronic devices.

In this study of premenopausal women with hormone receptor-positive breast cancer, BCI (H/I) status did not clearly predict greater benefit of adjuvant exemestane plus OFS vs tamoxifen plus OFS for women with BCI (H/I)-low tumors than for those with BCI (H/I)-high tumors; BCI continuous indices were reconfirmed as prognostic for premenopausal women. These findings support prior results of SOFT, which compared tamoxifen-alone vs OFS with either exemestane or tamoxifen, indicating premenopausal patients with BCI (H/I)-low tumors may benefit from more intensive endocrine therapy.

Limitations include sample size and underrepresentation of certain groups. Future studies should address these gaps and adjust for known risk factors to further clarify BCI's racial and ethnic implications.

"Hologic, Inc...today announced new data demonstrating the significant clinical impact of the Breast Cancer Index® (BCI®) test, which will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2025."

Here, we review the published data on the most common gene expression signatures (MammaPrint (MP), BluePrint (BP), Oncotype Dx, PAM50, the Breast Cancer Index (BCI), and EndoPredict (EP)) and their ability to predict the response to neoadjuvant treatment, as well as the possibility of using them on core needle biopsies. Additionally, we review the changes in the gene expression signatures after neoadjuvant treatment, and the ongoing clinical trials related to the utility of gene expression signatures in the neoadjuvant setting.

The adjusted BCI model identified women with early-stage, HR+ N0 breast cancer at minimal risk of DR who may consider de-escalating adjuvant endocrine therapy.

While multiple gene expression profiling tests are available, they classify patients differently and are not interchangeable; therefore, their application should be at the clinician's discretion during the decision-making process. It is essential that these tests are not the sole factor in determining the best treatment plan: other clinical considerations and patient preferences should also play a significant role in guiding treatment decisions.

"Four new studies regarding the Breast Cancer Index (BCI) test will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS). Among these studies, initial data will be premiered investigating the potential role of the BCI test to identify postmenopausal women with hormone-receptor positive (HR+), early-stage, node-negative disease who are at minimal risk of experiencing a distant recurrence. Full results will be shared during Poster Session 1 on December 11, 2024, at 12:30 p.m. CT [#P1-09-13]....Three additional investigational studies being presented at the SABCS conference related to the Breast Cancer Index test..."

Conclusions- We were able to confirm in this contemporary group the comparison findings of the 2016 TransATAC analysis that there can be a significant disparity between early recurrence risk as determined by the standard 30 or 70 gene expression profiles, and the BCI risk of late recurrence, as well as the potential benefit of longer term hormonal therapy in these patients. This suggests that the 11 gene BCI assay may be able to help patients decrease risk of late recurrences and avoid also unnecessary treatment related toxicity

Conclusions BCI (H/I) and BCI risk scores exhibited no correlation with BMI categories. BCI (H/I) consistently stratified patients into low- and high-likelihood for extended endocrine benefit independent of BMI categories, suggesting that BMI is not a reliable indicator for predicting recurrence risk or benefit from EET.

The updates to the NCCN and ASCO Guidelines led to a significant increase in utilization of the BCI test at all City of Hope sites of practice. We anticipate that the Epic software enhancement will lead to further utilization of the BCI test.

Performance of the adjusted BCI model was initially assessed in the tamoxifen-treated arm of the Stockholm trial (n=317) and then evaluated in a cohort from NCR (n=1247)... The current study demonstrates that an adjusted BCI minimal risk cut-point may identify postmenopausal women with HR+ N0 breast cancer, who are at sufficiently low risk of DR and thus unlikely to derive clinically meaningful benefit from adjuvant ET. These results support BCI as a biomarker to help guide the selection of HR+ breast cancer patients who could be spared from or consider shorter duration of adjuvant ET to avoid potentially serious side effects from these therapies.